SCHEMBL4711912

SCHEMBL4711912

CC(C)(C)OC(=O)N1CCC(Nc2ccc(Cl)cc2CCC(=O)O)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 3/20 0.50
ALDH1A1 P00352 2/20 0.50
NPC1 O15118 1/20 0.50
MAPT P10636 1/20 0.50
MAPK1 P28482 1/20 0.50
HTT P42858 1/20 0.50
RAB9A P51151 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
MAPK8 P45983 2/20 0.46
BRD4 O60885 1/20 0.46
STS P08842 5/20 0.45
NOS1 P29475 1/20 0.45
NOS2 P35228 1/20 0.45
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ENPP2 Q13822 1/20 0.43
TP53 P04637 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
USP30 Q70CQ3 1/20 0.43
CNR2 P34972 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4717960 0.89 NOS2 (0.52) CNR1ALDH1A1NPC1MAPTMAPK1
SCHEMBL3379625 0.88 ALDH1A1 (0.54) CNR1ALDH1A1NPC1MAPTMAPK1
SCHEMBL4713688 0.87 ALDH1A1 (0.53) CNR1ALDH1A1NPC1MAPTMAPK1
SCHEMBL6399839 0.85 CNR1 (0.43) CNR1NOS1NOS2ENPP2TP53
SCHEMBL31282736 0.82 ALDH1A1 (0.57) CNR1ALDH1A1NPC1MAPTMAPK1
SCHEMBL5121483 0.82 ALDH1A1 (0.57) CNR1ALDH1A1NPC1MAPTMAPK1
SCHEMBL6865007 0.81 ALDH1A1 (0.54) CNR1ALDH1A1NPC1MAPTMAPK1
SCHEMBL25390329 0.81 USP30 (0.59) CNR1ALDH1A1NPC1MAPTMAPK1
SCHEMBL22521596 0.81 ALDH1A1 (0.56) CNR1ALDH1A1NPC1MAPTMAPK1
SCHEMBL4716931 0.80 ALDH1A1 (0.57) CNR1ALDH1A1NPC1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1315490-B1 A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES ORTHO MCNEIL PHARM INC (US) 2008-11-12 EP disclosed
US-20070117785-A1 Substituted pyrazoles and methods of treatment with substituted pyrazoles JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-24 US disclosed
EP-1309593-B1 SUBSTITUTED PYRAZOLES ORTHO MCNEIL PHARM INC (US) 2006-03-15 EP disclosed
US-20050245576-A1 Substituted pyrazoles BUTLER CHRISTOPHER R 2005-11-03 US disclosed
US-6953793-B2 Substituted pyrazoles ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2005-10-11 US disclosed
US-20050101587-A9 Method for treating allergies using substituted pyrazoles ORTHO MCNEIL PHARMACEUTICALS, INC. 2005-05-12 US disclosed
US-6583155-B2 Administering 2-(1-(3-(5-Acetyl-3-(4-chloro-phenyl)-4,5,6,7-tetrahydro-pyrazolo-(4,3 -c)pyridin-1-yl)-2-hydroxy-propyl)-piperidin-4-ylamino)-benzonitrile for inhibiting cathepsins; for treating atopic diseases ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-06-24 US disclosed
EP-1315490-A2 A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES Ortho-McNeil Pharmaceutical, Inc. (US) 2003-06-04 EP disclosed
EP-1309593-A2 SUBSTITUTED PYRAZOLES Ortho-McNeil Pharmaceutical, Inc. (US) 2003-05-14 EP disclosed
US-20030078419-A1 Substituted pyrazoles ORTHO MCNEIL PHARMACEUTICAL, INC. 2003-04-24 US disclosed
US-20030022903-A1 Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation RICKS MICHAEL J (US) 2003-01-30 US disclosed
US-20020115656-A1 Method for treating allergies using substituted pyrazoles BUTLER CHRISTOPHER R (US) 2002-08-22 US disclosed
US-20020055497-A1 Method for treating allergies using substituted pyrazoles BUTLER CHRISTOPHER R (US) 2002-05-09 US disclosed
WO-2002020011-A2 A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2002-03-14 WO disclosed
WO-2002014315-A2 SUBSTITUTED PYRAZOLES ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2002-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245576-A1 Substituted pyrazoles CTSS, CTSZ, CTSV CNR1 2781/4885ALDH1A1 2313/4885NPC1 918/4885
US-20030078419-A1 Substituted pyrazoles CTSS, CTSZ, CTSV CNR1 2781/4885ALDH1A1 2313/4885NPC1 918/4885
US-20030022903-A1 Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation CYP4X1, NAT1, CYP1A1 CNR1 1851/4885ALDH1A1 230/4885NPC1 1279/4885
US-20020115656-A1 Method for treating allergies using substituted pyrazoles TSLP, IL33, HRH2 CNR1 1665/4885ALDH1A1 1241/4885NPC1 1425/4885
US-20050101587-A9 Method for treating allergies using substituted pyrazoles TSLP, IL33, HRH2 CNR1 1665/4885ALDH1A1 1241/4885NPC1 1425/4885
US-20020055497-A1 Method for treating allergies using substituted pyrazoles TSLP, IL33, HRH2 CNR1 1665/4885ALDH1A1 1241/4885NPC1 1425/4885
US-20070117785-A1 Substituted pyrazoles and methods of treatment with substituted pyrazoles CTSS, CMA1, CTSZ CNR1 2474/4885ALDH1A1 2126/4885NPC1 1383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.